Sikander Ailawadhi
0000-0002-8377-8111
Publication & Citation Trends
Publications
0 total
Real-World Outcomes and Risk Factors in Multiple Myeloma Pts Receiving Cilta-Cel Including Functional High-Risk Status
Cited by 0
Semantic Scholar
CAR T-Cell Therapy Outcomes in Plasma Cell Leukemia
Cited by 0
Semantic Scholar
KarMMa-3 Subgroup Analysis in Older Patients with Relapsed/Refractory Multiple Myeloma Treated with Idecabtagene Vicleucel
Cited by 0
Semantic Scholar
Investigating the Role of Dexamethasone Prophylaxis for the Risk Reduction of Immune Effector Cell Delayed Neurotoxicity in Cilta-Cel Treated Patients
Cited by 0
Semantic Scholar
Outcomes of Concomitant Autoimmune Diseases in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies
Cited by 0
Semantic Scholar
POD24 is a Novel Determinant of Prognosis in Patients with Waldenström Macroglobulinemia.
Cited by 1
Semantic Scholar
Belantamab Mafodotin in Patients With Relapsed/Refractory Multiple Myeloma and Severe Renal Impairment (Including Dialysis): Results From the Phase I DREAMM-12 Study
Cited by 0
Semantic Scholar
Risk Factors for Delayed Neurotoxicity in Patients with Relapsed Myeloma Who Received Ciltacabtagene Autoleucel (cilta-cel)
Cited by 5
Semantic Scholar
Research Topics
Multiple Myeloma Research and Treatments
(355)
Chronic Lymphocytic Leukemia Research
(213)
Protein Degradation and Inhibitors
(132)
Chronic Myeloid Leukemia Treatments
(79)
Lymphoma Diagnosis and Treatment
(74)
Affiliations
Buffalo State University
University of Southern California
Texas Tech University
Roswell Park Comprehensive Cancer Center
Allegheny Health Network